Genentech Files sBLA for Avastin for First-Line NSCLC Treatment
Genentech Files sBLA for Avastin for First-Line NSCLC Treatment
SOUTH SAN FRANCISCOGenentech Inc. has submitted a supplemental Biologics License Application (sBLA) to FDA for bevacizumab (Avastin) in combination with platinum-based chemotherapy for first-line treatment of advanced, non-squamous, non-small-cell lung cancer (NSCLC). The company has requested priority review on the submission. In a phase III trial (E4599) in patients with locally advanced, metastatic, or recurrent NSCLC, Avastin plus paclitaxel and carboplatin improved overall survival by 25%, compared with chemotherapy alone.
Articles in this issue
NCCN Soft-Tissue Extremity Sarcoma Guidelines Clarify Follow-up Schedule
Genentech Files sBLA for Avastin for First-Line NSCLC Treatment
RFA Effective for Single, Small Hepatocellular Carcinoma
New Imaging, ChemoRT Recommendations From NCCN
Panitumumab Improves PFS in Advanced Colon Ca
Studies Question Watchful Waiting for Some Prostate Ca Pts
Growing Evidence Supports Stem Cell Hypothesis of Cancer
FDA Approves New Every-3-Week Dosing for Aranesp
Telephone Often Delivers News of Breast Cancer Diagnosis
IND Submitted for CYT-500
Lower-Dose Thalidomide Effective in Relapsed or Refractory Multiple Myeloma, With Less Toxicity
Zometa Increases BMD in Breast Ca Patients on Femara
Prostate Cancer Recurrence Linked to Surgeon's Skill
FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib
Automated Voice System Manages Chemo Symptoms
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
